Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06327971
  4. Details
NCT06327971 Clinical Trial

Enhanced Outcome Prediction in Cutaneous Squamous Cell Carcinoma Using Deep-learning and Computational Histopathology

Squamous Cell Carcinoma of the Skin Clinical Trial

Official title:
Enhanced Outcome Prediction in Cutaneous Squamous Cell Carcinoma Using Deep-learning and Computational Histopathology

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT06327971
Other study ID # 0000
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date October 20, 2023
Est. completion date October 2028

Study information
Verified date February 2024
Source Queen Mary University of London
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Evaluate a deep-learning model trained on computational histopathology for predicting outcomes in cutaneous squamous cell carcinoma

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 300
Est. completion date October 2028
Est. primary completion date October 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Histologically-confirmed diagnosis of primary cutaneous squamous cell carcinoma

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
United Kingdom Barts Health NHS Trust London

Sponsors (1)
Lead Sponsor Collaborator
Queen Mary University of London

Country where clinical trial is conducted

United Kingdom, 

Outcome
Type Measure Description Time frame Safety issue
Primary Metastasis 3 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03291002 - Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC Phase 1
Not yet recruiting NCT03621462 - Elucid Labs AIDA™ - Labelled Image Acquisition Protocol N/A
Not yet recruiting NCT04480645 - CivaDerm(TM) Surface Therapy Pilot Study Early Phase 1
Recruiting NCT03370861 - How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
Recruiting NCT06014086 - Intratumoral PH-762 for Cutaneous Carcinoma Phase 1
Completed NCT02347813 - Preventing Squamous Cell Skin Cancer Phase 2
Terminated NCT01984892 - Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) Phase 2
Completed NCT00563290 - Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia Phase 2
Recruiting NCT04204837 - Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin Phase 2
Completed NCT03894618 - SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Phase 1
Terminated NCT01823679 - Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin Phase 2
Completed NCT00126555 - Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer Phase 2
Completed NCT00089180 - T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant Phase 2
Not yet recruiting NCT05246228 - Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy
Recruiting NCT05886140 - Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin N/A
Completed NCT02324608 - Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer N/A
Recruiting NCT02717936 - Investigation of Desmoplastic Squamous Cell Carcinoma N/A
Recruiting NCT05482880 - Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region
Withdrawn NCT01465815 - Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN) Phase 1/Phase 2
Recruiting NCT05490485 - Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma Phase 2